

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/236221258>

New derivatives of pyrimidine nucleosides: Synthesis, physico-chemical properties and biological activity

ARTICLE in JOURNAL OF HETEROCYCLIC CHEMISTRY · MAY 1988

Impact Factor: 0.79 · DOI: 10.1002/jhet.5570250365

CITATIONS

3

READS

14

6 AUTHORS, INCLUDING:



Lorenzo De Napoli

University of Naples Federico II

12 PUBLICATIONS 57 CITATIONS

[SEE PROFILE](#)



Simonetta Bartolucci

University of Naples Federico II

116 PUBLICATIONS 1,981 CITATIONS

[SEE PROFILE](#)



Gennaro Piccialli

University of Naples Federico II

173 PUBLICATIONS 1,643 CITATIONS

[SEE PROFILE](#)

New Derivatives of Pyrimidine Nucleosides: Synthesis, Physico-Chemical Properties and Biological Activity

Lorenzo de Napoli and Luciano Mayol*

Dipartimento di Chimica delle Sostanze Naturali, Università di Napoli, Via L. Rodinò 22,
I-80138 Napoli, Italy

Simonetta Bartolucci, Gennaro Piccialli, Mosé Rossi and Ciro Santacroce

Dipartimento di Chimica Organica e Biologica, Università di Napoli, Via Mezzocannone 16,
I-80134 Napoli, Italy

Received April 16, 1987

The paper reports the synthesis and physico-chemical data of eight new pyrimidine nucleosides C-4 substituted and two imidazo[1,2-c]pyrimidine nucleosides as well as preliminary results of their biological effects on neuroblastoma cells in culture.

J. Heterocyclic Chem., **25**, 1039 (1988).

A number of modified pyrimidine nucleosides are known as minor components of nucleic acids, and some of them, exhibiting rather complex structures, have also been isolated from marine sponges and from microbiological sources.

Metabolic derivatives of the major pyrimidine nucleosides seem to play an important biological role in the cell, especially in the organizational process of DNA and RNA, in their interactions and in the regulation of genetic expression.


Synthetic structural analogues may either interfere with nucleoside synthesis, interacting with enzymes of the nucleic acid metabolism, or exert their effects after incorporation, for example, into DNA [1,2]. In the latter instance this incorporation can lead to gene activation, as is the case of 5-aza-2'-deoxycytidine, or can cause chain termination, as is the case of dideoxynucleotides or azidothymidine. Some of these analogues, which exert anti-cancer and/or antiviral activity, are currently used in

therapy. New synthetic approaches with the aim of discovering compounds with useful biological activity are necessary to exploit the specificity differences, often unpredictable, of the enzymatic activity of invading agents and host cells [3-5].

The structural modifications of nucleosides that can be created are practically unlimited.

Nucleosides containing modified carbohydrate moieties have frequently been prepared *via* glycosylation of the base with a suitable derivative of the desired sugar. Alternatively, efforts have been made to develop specific chemical transformations suitable for introducing the desired modifications into the sugar moiety of nucleosides.

In a related way, base analogues have been prepared *via* *N*-glycosilation of suitably modified heterocycles or by structural transformation of the base moiety of existing nucleosides [6]. The latter approach has led to a method widely used in the preparation of antitumor agents involv-



	R ¹	R ²
1	Cl	-COCH ₃
2	-NHNNH ₂	-H
3	-NH(CH ₂) ₂ NH ₂	-H
4	-NHCH ₂ COOEt	-COCH ₃
5	-NH(CH ₂) ₂ COCH	-COCH ₃
6	-NHCH ₂ CH(OCH ₃) ₂	-COCH ₃
7	-NHCH ₂ COOH	-H
8	-NH(CH ₂) ₂ COOH	-H
9	-NHCH ₂ CH(OCH ₃) ₂	-H

ing isosteric replacements in natural metabolites.

This paper deals with the synthesis and physicochemical characterization of eight pyrimidine nucleosides C-4 substituted, **2-9**, and two imidazo[1,2-c]pyrimidine nucleosides **10,11**. Data on the inhibitory effect that these compounds exert on the *in vitro* cell growth are also reported.

Synthesis of the derivatives was carried out on the basis of: a) the role of nitrogen atoms in the binding sites of biological systems, b) the occurrence in nature of several pyrimidylaminoacids as antibiotics or as intermediates in the biosynthesis of nucleosides, and c) the potential capacity of imidazo[1,2-c]pyrimidine derivatives to either emulate or antagonize the function of the naturally occurring nucleosides [7-9].

Compounds **2-11** were synthesized from a C-4 chlorine derivative of thymidine (**1**), which proved to be a good synthon for different substitutions in the 4-position of the pyrimidine ring under very mild conditions [10,11].

Compound **1**, by treatment with anhydrous hydrazine (excess) and ethylendiamine (excess) for 2 and 5 hours at room temperature, afforded **2** and **3** in almost quantitative yields respectively. Structures **2** and **3** were assigned on the basis of their elemental analysis, uv, ms, ¹H- and ¹³C-nmr. Furthermore, the structure of compound **2** was confirmed by its conversion into 6-(2-deoxy- β -D-*erythro*-pentofuranosyl)-8-methyltetrazolo[1,5-c]pyrimidin-5(6H)-one [11] by treatment with sodium nitrite/hydrochloric acid.

Compounds **4, 5** and **6** were synthesized by the reaction of compound **1** with glycine ethyl ester hydrochloride (dimethylformamide/triethylamine, 15 hours, 50°), 3-amino propanoic acid (dimethylformamide/triethylamine, 15 hours, 50°) and 2,2-dimethoxyethylamine (acetonitrile, 1 hour, room temperature) respectively. Compounds **4-6** were purified by silica gel chromatography and their structures confirmed by elemental analysis, uv, ms, ¹H- and ¹³C-nmr spectra.

Treatment of compounds **5** and **6** with concentrated ammonia/dioxane (1:1) for 24 hours at room temperature afforded the relative deacetyl derivatives **8** and **9**. Compound **4** in the same hydrolytic conditions, yielded the acid **7**. Structures **7-9** were confirmed by elemental analysis and spectroscopic data.

In order to obtain an imidazo[1,2-c]pyrimidine derivative *via* an intramolecular cyclization, we treated compound **9** with hydrochloric acid 0.5 N at 50° for 5 hours; after purification by silica gel chromatography, we obtained the compounds **10** and **11**. Spectroscopic analysis revealed that both are mixtures of epimers at C-3.

Preliminary analysis of the biological activity of compounds **2, 3, 7, 8, 9, 10** and **11** was made by determining their effect on murine 41 A 3 neuroblastoma cells in culture.

In order to evaluate the therapeutic potential of these compounds, we studied their effect on the growth of the neuroblastoma cells and on DNA synthesis. In both studies the cells were treated for 24 hours with the indicated compounds.

When the cells were treated with compounds **3, 8, 10** and **11** at a concentration of 10⁻⁴ M, the growth inhibition effect was 10%. Compound **9** had a growth inhibition effect of 15% and compounds **2** and **7** of 25%.

To evaluate the effect on DNA synthesis, the cells were treated with compounds **2** and **7** at a concentration of 10⁻⁵ M. Determination of the amount of radioactivity incorporated into DNA was made after a 4 hours pulse with methyl-³H-thymidine (41 Ci/mmole). Compound **2** had a DNA synthesis inhibition effect of 7% and compound **7** of 15%.

EXPERIMENTAL

All the reagents for the synthesis are commercially available (Merck). The ¹H- and ¹³C-nmr Fourier-transform spectra were recorded with a Bruker WM-250. The uv spectra were taken on a Perkin Elmer 550 S spectrophotometer. The ms were taken on a Kratos MS 50 instrument. 1-(2-Deoxy- β -D-*erythro*-pentofuranosyl)-4-hydrazino-5-methylpyrimidin-2(1H)-one (**2**).

Compound **1** (200 mg, 0.58 mmole) was treated with excess anhydrous hydrazine at room temperature for 2 hours. The resulting solution was dried *in vacuo* and dissolved in methanol. Thin layer chromatography analysis (silica gel, eluent chloroform/methanol 98:2) indicated that the starting compound **1** was completely converted into baseline material. The crude mixture was chromatographed on preparative layer chromatography (silica gel, eluent 1-butanol/acetic acid/water, 60:15:25); the band Rf 0.20 (uv light) eluted with methanol afforded 130 mg of **2** (89% yield). Recrystallization from methanol gave an analytically pure sample mp = 111-113°; $[\alpha]_D$ = 17.4 (c = 1, methanol); λ_{max} (methanol) = 277 nm, (ϵ = 7200); ms: (chemical ionization) gave significant ions at m/z 257 (MH)⁺, 141 (base moiety + 2H)⁺, 99 (sugar moiety - H₂O)⁺ and 81 (sugar moiety - 2H₂O)⁺; ¹H-nmr (perdeuteriomethanol, 250 MHz): δ 7.28 (1H, bs, H-6), 6.00 (1H, dd, H-1'), 4.30 (1H, m, H-3'), 3.89 (1H, m, H-4'), 3.75 (2H, m, H₂-5'), 2.42 (1H, m, Ha-2'), 2.32 (1H, m, Hb-2'), 2.12 (3H, bs, CH₃-C-5); ¹³C-nmr (perdeuteriomethanol, 62.9 MHz): δ 172.4 (C-2), 157.9 (C-4), 137.7 (CH-6), 104.1 (C-5), 88.8 (CH-1'), 87.2 (CH-3'), 72.2 (CH-4'), 63.0 (CH₂-5'), 41.6 (CH₂-2'), 12.8 (CH₃-C-5).

Anal. Calcd. for C₁₀H₁₆N₄O₄: C, 46.87; H, 6.29; N, 21.87. Found: C, 46.95; H, 6.34; N, 21.89.

1-(2-Deoxy- β -D-*erythro*-pentofuranosyl)-4-[(2-aminoethyl)-amino]-5-methylpyrimidin-2(1H)-one (**3**).

Compound **1** (200 mg, 0.58 mmole) was treated with an excess of anhydrous ethylendiamine (freshly distilled) at room temperature for 5 hours. The reaction mixture, dried *in vacuo*, was chromatographed on preparative layer chromatography (silica gel, 0.5 mm, eluent ethanol-water/ammonium hydroxide, concentrated, 80:16:4); the band Rf 0.4 (uv light) eluted with methanol afforded 130 mg of **3** (80% yield). Recrystallization from methanol gave an analytically pure sample mp 113-115°; $[\alpha]_D$ = 38.4 (c = 1, methanol); λ_{max} (methanol): 278 nm (ϵ = 8100); ms: (chemical ionization) gave significant ions at m/z 285 (MH)⁺, 267 (MH - H₂O)⁺, 169 (base moiety + 2H)⁺ and 117 (sugar moiety)⁺; ¹H-nmr (perdeuteriomethanol, 250 MHz): δ 7.80 (1H, bs, H-6), 6.29 (1H, dd, H-1'), 4.22 (1H, m, H-3'), 3.93 (1H, m, H-4'), 3.80 (2H, m, H₂-5'), 3.56 (2H, t, -CH₂-CH₂-NH₂), 2.87 (2H, t, -CH₂-CH₂-NH₂), 2.33 (1H, m, Ha-2'), 2.16 (1H, m, Hb-2'), 1.97 (3H, bs, CH₃-C-5); ¹³C-nmr (deuterium oxide, 62.9 MHz): δ

166.8 (C-2), 159.9 (C-4), 139.3 (CH-6), 107.5 (C-5), 88.7 (CH-1'), 88.0 (CH-3'), 72.9 (CH-4'), 63.7 (CH₂-5'), 44.8 and 42.1 (-CH₂-CH₂-NH₂), 41.4 (CH₂-2'), 14.4 (CH₃-C-5).

Anal. Calcd. for C₁₈H₂₀N₄O₄: C, 50.69; H, 7.09; N, 19.71. Found: C, 50.78; H, 7.13; N, 19.82.

1-(2-Deoxy-3,5-di-O-acetyl-β-D-*erythro*-pentofuranosyl)-4-[(ethoxycarbonylmethyl)amino]-5-methylpyrimidin-2(1*H*)-one (**4**).

Compound **1** (200 mg, 0.58 mmole) was treated in anhydrous dimethylformamide (3 ml) with 400 mg of glycine ethyl ester hydrochloride and 2 ml of anhydrous triethylamine and the mixture was stirred for 15 hours at 50°. After removal of the solvent *in vacuo* the solid residue was suspended in water and extracted with chloroform. The organic phase was evaporated to dryness *in vacuo* and the residue was chromatographed on preparative layer chromatography (silica gel, eluent chloroform/methanol, 95:5); the band Rf 0.5 (uv light) eluted with chloroform/methanol, 9:1, afforded 120 mg of **4** (50% yield). Recrystallization from methanol gave an analytically pure sample, mp = 157-158°; [α]_D = 24.4 (c = 1, chloroform); λ max (chloroform): 282 nm (ε = 7500); ms: (chemical ionization) gave significant ions at m/z 412 (MH)⁺, 352 (MH-CH₃COOH)⁺, 292 (MH-2CH₃COOH)⁺ and 212 (base moiety + 2H)⁺; ¹H-nmr (deuteriochloroform, 250 MHz): δ 7.39 (1H, bs, H-6), 6.34 (1H, dd, H-1'), 5.23 [1H, bt, -NH-CH₂-CH(OCH₃)₂], 5.14 (1H, m, H-3'), 4.46 [1H, t, -CH₂-CH(OCH₃)₂], 4.31 (2H, m, H₂-5'), 4.21 (1H, m, H-4'), 3.66 [2H, bt, -CH₂-CH(OCH₃)₂], 3.37 (6H, s, OCH₃), 2.57 (1H, m, Ha-2'), 2.06 and 2.06 (3H each, s, CH₃CO), 2.04 (1H, m, Hb-2'), 1.90 (3H, bs, CH₃-C-5); ¹³C-nmr (deuteriochloroform, 62.9 MHz): δ 170.2 and 170.1 (2CH₃CO), 163.1 (C-2), 155.7 (C-4), 136.2 (CH-6), 102.2 [CH(OCH₃)₂], 101.8 (C-5), 85.9 (CH-1'), 81.9 (CH-3'), 74.2 (CH-4'), 63.8 (CH₂-5'), 54.4 (2-OCH₃), 43.2 [-CH₂-CH(OCH₃)₂], 38.2 (CH₂-2'), 20.7 and 20.6 (CH₃-CO-), 12.9 (CH₃-C-5).

Anal. Calcd. for C₁₈H₂₇N₃O₆: C, 52.29; H, 6.58; N, 10.16. Found: C, 52.39; H, 6.65; N, 10.21.

1-(2-Deoxy-β-D-*erythro*-pentofuranosyl)-4-[(carboxymethyl)amino]-5-methylpyrimidin-2(1*H*)-one (**7**).

Compound **4** (100 mg, 0.24 mmole) was treated with concentrated ammonia/dioxane (1:1) (10 ml) at room temperature for 24 hours. The resulting solution was dried *in vacuo* and the residue was dissolved in water and lyophilized. Thin layer chromatography analysis (silica gel, eluent: 1-butanol/acetic acid/water, 60:15:25) indicated that the compound **4** was completely converted into only one product (Rf 0.3, uv light) identified as **7**. Recrystallization from ethanol gave an analytically pure sample mp 110-113°; [α]_D = 37.0 (c = 1 in methanol); λ max (methanol): 277 nm (ε = 7800); ms: (chemical ionization) gave significant ions at m/z 300 (MH)⁺, 282 (MH-H₂O)⁺ and 184 (base moiety + 2H)⁺; ¹H-nmr (perdeuteriomethanol, 250 MHz): δ 7.85 (1H, bs, H-6), 6.28 (1H, dd, H-1'), 4.39 (1H, m, H-3'), 4.13 (2H, bs, -CH₂-COOH), 3.94 (1H, m, H-4'), 3.80 (2H, m, H₂-5'), 2.36 (1H, m, Ha-2'), 2.16 (1H, m, Hb-2'), 1.96 (3H, bs, CH₃-C-5); ¹³C-nmr (perdeuteriomethanol, 62.9 MHz): δ 174.4 (COOH), 165.1 (C-2), 158.4 (C-4), 139.3 (CH-6), 105.0 (C-5), 88.8 (CH-1'), 87.5 (CH-3'), 72.0 (CH-4'), 62.8 (CH₂-5'), 44.5 (-CH₂-COOH), 41.9 (CH₂-2'), 12.9 (CH₃-C-5).

Anal. Calcd. for C₁₂H₁₇N₃O₆: C, 48.16; H, 5.73; N, 14.04. Found: C, 48.25; H, 5.81; N, 14.16.

1-(2-Deoxy-β-D-*erythro*-pentofuranosyl)-4-[(2-carboxyethyl)amino]-5-methylpyrimidin-2(1*H*)-one (**8**).

Compound **5** (100 mg, 0.25 mmole) was treated with concentrated ammonia/dioxane (1:1) (10 ml) at room temperature for 24 hours. The resulting solution was dried *in vacuo* and the residue was dissolved in water and lyophilized. Thin layer chromatography analysis (silica gel, eluent: 1-butanol/acetic acid/water, 60:15:25) indicated that the compound **5** was converted into corresponding deacetylated compound **8** (Rf 0.35, uv light, quantitative yield). Recrystallization from ethanol gave an analytically pure sample mp 135-138°; [α]_D = 25.0 (c = 1, methanol); λ max (methanol): 278 nm (ε = 7100); ms: (chemical ionization) gave significant ions at m/z 314 (MH)⁺, 198 (base moiety + 2H)⁺, 117 (sugar moiety)⁺ and 81 (sugar moiety - 2H₂O)⁺; ¹H-nmr (perdeuteriomethanol, 250 MHz): δ 7.78 (1H, bs, H-6), 6.30 (1H, dd, H-1'), 4.41 (1H, m, H-3'), 3.94 (1H, m, H-4'), 3.80 (2H, m, H₂-5'), 3.7 (2H, bt, -CH₂-COOH), 2.55 (2H, bt, -CH₂-CH₂-COOH), 2.33 (1H, m, Ha-2'), 2.18 (1H, m, Hb-2'), 1.97 (3H, bs, CH₃-C-5); ¹³C-nmr (perdeuteriomethanol, 62.9 MHz): δ 180.2 (-COOH), 164.7 (C-2), 158.8 (C-4), 138.7 (CH-6), 105.0 (C-5), 88.8 (CH-1'), 87.4 (CH-3'), 72.1 (CH-4'), 62.9 (CH₂-5'), 41.8 (CH₂-2'), 38.7 (-CH₂-CH₂-COOH), 36.5 (-CH₂-CH₂-COOH), 12.9 (CH₃-C-5).

Anal. Calcd. for C₁₃H₁₉N₃O₆: C, 49.83; H, 6.11; N, 13.41. Found: C, 49.88; H, 6.10; N, 13.43.

1-(2-Deoxy-β-D-*erythro*-pentofuranosyl)-4-[(2,2-dimethoxyethyl)amino]-5-methylpyrimidin-2(1*H*)-one (**9**).

Compound **6** (100 mg, 0.24 mmole) was treated with concentrated ammonia/dioxane (1:1) (10 ml) at room temperature for 24 hours. The resulting solution was dried *in vacuo* and the residue was dissolved in

1-(2-Deoxy-3,5-di-O-acetyl-β-D-*erythro*-pentofuranosyl)-4-[(2,2-dimethoxyethyl)amino]-5-methylpyrimidin-2(1*H*)-one (**6**).

Compound **1** (200 mg, 0.58 mmole) was treated in anhydrous acetonitrile (3 ml) with 0.6 ml of 2,2-dimethoxyethylamine and the mixture allowed to stand for 1 hour at room temperature. The reaction mixture, dried *in vacuo*, was chromatographed on preparative layer chromatography (silica gel, eluent chloroform/methanol 9:1); the band Rf 0.5 (uv

water and lyophilized. Thin layer chromatography analysis (silica gel, eluent: chloroform/methanol, 85:15) indicated that the compound **6** was completely converted into the corresponding deacetylated **9** (*Rf* 0.2, uv light). Recrystallization from ethanol/chloroform gave an analytically pure sample mp 130-132°; $[\alpha]_D = 43.0$ (*c* = 1, methanol); λ_{max} (methanol): 277 nm (ϵ = 8500); ms: (chemical ionization) gave significant ions at *m/z* 330 (MH)⁺, 266 (MH-2CH₃OH)⁺, 214 (base + 2H)⁺ and 117 (sugar moiety)⁺; ¹H-nmr (perdeuteriomethanol, 250 MHz): δ 7.81 (1H, bs, H-6), 6.29 (1H, dd, H-1'), 4.70 [1H, t, -CH₂CH(OCH₃)₂], 4.40 (1H, m, H-3'), 3.94 (1H, m, H-4'), 3.80 (2H, m, H₂-5'), 3.59 [2H, d, -CH₂CH(OCH₃)₂], 3.42 (6H, s, 2-OCH₃), 2.35 (1H, m, Ha-2'), 2.17 (1H, m, Hb-2'), 1.97 (3H, bs, CH₃-C-5); ¹³C-nmr (perdeuteriomethanol, 62.9 MHz): δ 165.0 (C-2), 158.4 (C-4), 139.0 (CH-6), 104.7 (C-5), 103.6 [-CH(OCH₃)₂], 88.7 (CH-1'), 87.4 (CH-3'), 72.0 (CH-4'), 62.8 (CH₂-5'), 54.7 (2-OCH₃), 43.6 [-CH₂CH(OCH₃)₂], 41.9 (CH₂-2'), 13.0 (CH₃-C-5).

Anal. Calcd. for C₁₄H₂₃N₃O₆: C, 51.05; H, 7.04; N, 12.76. Found: C, 51.00; H, 7.08; N, 12.82.

3-Hydroxy-2,3-dihydro-6-(2-deoxy- β -D-*erythro*-pentofuranosyl)-8-methylimidazo[1,2-c]pyrimidin-5(*H*)-one (**10**) and 3-Methoxy-2,3-dihydro-6-(2-deoxy- β -D-*erythro*-pentofuranosyl)-8-methylimidazo[1,2-c]pyrimidin-5(*H*)-one (**11**).

Compound **9** (100 mg, 0.30 mmole) was treated with hydrochloric acid 0.5 *N* (20 ml) at 50° for 5 hours. The resulting mixture was neutralized with excess Dowex AG1-X8 (OH⁻) resin. The filtered solution was dried *in vacuo* and the residue, dissolved in methanol was chromatographed on preparative layer chromatography (silica gel, 0.5 mm, eluent chloroform/methanol, 83:17). The bands *Rf* 0.15 and 0.35 (uv light), eluted with chloroform/methanol 7:3, afforded respectively 30 mg of **10** (34% yield) and 15 mg of **11** (12% yield). The ¹H- and ¹³C-nmr spectra showed that the products **10** and **11** are mixtures (in a ratio 2:1) of two epimers at C-3, through the splitting of some of the signals (H-7, H-1', C-1', C-4', C-5', CH₃-C-8 for **10** and C-3, C-3, and -OCH₃ for **11**).

The product **10** had: λ_{max} (methanol): 279 nm (ϵ = 9300); ms: (chemical ionization) gave significant ions at *m/z* 266 (MH-H₂O)⁺, 230 (MH-3H₂O)⁺ 168 (base moiety + 2H)⁺ 150 (base moiety + 2H-H₂O)⁺ and 117 (sugar moiety)⁺; ¹H-nmr (perdeuteriomethanol, 250 MHz): δ 7.63 and 7.52 (1H, bs's, H-7), 6.37 and 6.31 (1H, dd's, H-1'), 4.67 (1H, m, H-3), 4.42 (1H, m, H-3'), 3.94 (1H, m, H-4'); 3.79 (2H, m, H₂-5'), 3.55 (2H, m, H₂-2), 2.18 (1H, m, Ha-2'), 2.03 (1H, m, Hb-2'), 1.80 (3H, bs, CH₃-C-8); ¹³C-nmr (perdeuteriomethanol, 62.9 MHz): δ 157.0 (C-5), 151.3 (C-9), 138.9 (CH-7), 104.7 (C-8), 97.0 (C-3), 88.7 and 88.5 (CH-1'), 87.4 (CH-3'), 72.3 and 72.0 (CH-4'), 63.0 and 62.8 (CH₂-5'), 46.8 (CH₂-2), 41.9 (CH₂-2'), 13.1 and 12.8 (CH₃-C-8).

Anal. Calcd. for C₁₃H₁₇N₃O₅: C, 50.88; H, 6.05; N, 14.83. Found: C, 50.87; H, 6.14; N, 14.94.

The product **11** had: λ_{max} (methanol): 280 nm (ϵ = 8800); ms: (chemical ionization) gave significant ions at *m/z* 298 (MH)⁺, 182 (base moiety + 2H)⁺, 150 (base moiety + 2H-CH₃OH)⁺ and 117 (sugar moiety)⁺; ¹H-nmr (perdeuteriomethanol, 250 MHz): δ 7.42 (1H, bs, H-7), 6.32 (1H, dd, H-1'), 5.70 (1H, m, H-3), 4.40 (1H, m, H-3'), 3.95 (2H, m, H₂-2), 3.90 (1H, m, H-4'), 3.76 (2H, m, H₂-5'), 3.49 (3H, s, -OCH₃), 2.20 (2H, m, H₂-2'), 1.94 (3H, bs, CH₃-C-8); ¹³C-nmr (perdeuteriomethanol, 62.9 MHz): δ 156.6 (C-5), 150.3 (C-9), 134.3 (CH-7), 107.1 (C-8), 89.4 and 89.3 (C-3), 88.6 (CH-1'), 86.3 and 86.1 (CH-3'), 72.3 (CH-4'), 63.0 (CH₂-5'), 60.4 (CH₂-2), 57.1 and 56.9 (-OCH₃), 40.7 (CH₂-2'), 13.1 (CH₃-C-8).

Anal. Calcd. for C₁₃H₁₉N₃O₅: C, 52.51; H, 6.44; N, 14.13. Found: C, 52.56; H, 6.49; N, 14.21.

Acknowledgements.

This work was supported by: CNR, Progetto Finalizzato Oncologia, Progetto Finalizzato Chimica Fine e Secondaria and M.P.I.. Mass spectral data were provided by "Servizio di Spettrometria di Massa del CNR e dell'Università di Napoli".

REFERENCES AND NOTES

- [1] P. V. Danenber, *Biochim. Biophys. Acta*, **473**, 73 (1977).
- [2] P. G. W. Plageman, R. Marz and R. N. Wohlheiter, *Cancer Res.*, **38**, 978 (1978).
- [3] "Nucleoside Analogues. Chemistry, Biology and Medical Applications", R. T. Walker, E. De Clerq and F. Eckstein, eds, Plenum Press, New York and London, 1979.
- [4] "Nucleosides, Nucleotides and their Biological Applications", Proceedings of the 5th International Round Table, J. L. Rideout, B. W. Henry and L. M. Beacham III, eds, Academic Press, Inc, New York, 1982.
- [5] F. Eckstein, *Angew. Chem., Int. Ed. Engl.*, **22**, 423 (1983).
- [6] "Synthetic Procedures in Nucleic Acid Chemistry", Vol 1, W. W. Zorbach and R. Stuart Tipson, eds, John Wiley & Sons, New York, 1968.
- [7] D. G. Bartholomew, P. Dea, R. K. Robins and G. R. Revankar, *J. Org. Chem.*, **40**, 3708 (1975).
- [8] K. L. Nagpal, M. M. Dhar, *Tetrahedron*, **23**, 1297 (1967).
- [9] V. Nair, R. J. Offerman and G. A. Turner, *J. Org. Chem.*, **49**, 4021 (1984).
- [10] L. Mayol, G. Piccialli, M. Rossi and C. Santacroce, *Gazz. Chim. Ital.*, **113**, 863 (1983).
- [11] L. De Napoli, L. Mayol, G. Piccialli, M. Rossi and C. Santacroce, *J. Heterocyclic Chem.*, **23**, 1401 (1986).